CGTX — Cognition Therapeutics Balance Sheet
0.000.00%
- $27.63m
- $2.62m
Annual balance sheet for Cognition Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 5.19 | 54.7 | 41.6 | 29.9 | 25 |
Net Total Receivables | 1.15 | 2.27 | 3.67 | 1.28 | 2.69 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 6.91 | 59 | 47.6 | 34.2 | 29.6 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.211 | 0.145 | 1.05 | 0.941 | 0.679 |
Other Long Term Assets | |||||
Total Assets | 7.12 | 59.1 | 50.4 | 35.2 | 30.2 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3.25 | 7.86 | 7.79 | 10.2 | 11.1 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 19.9 | 7.86 | 10.2 | 10.7 | 11.5 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -12.8 | 51.3 | 40.2 | 24.5 | 18.8 |
Total Liabilities & Shareholders' Equity | 7.12 | 59.1 | 50.4 | 35.2 | 30.2 |
Total Common Shares Outstanding |